Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10

Urology

Volumn 52, Issue 2, 1998, Pages 268-276

  Poppas, Dix P ^a   Pavlovich, Christian P ^b   Folkman, Judah ^b   Voest, Emile E ^b   Chen, Xiaohong ^b   Luster, Andrew D ^b   O'Donnell, Michael A ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BCG VACCINE; CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUPERFICIAL CANCER; SUPERNATANT; TRANSITIONAL CELL CARCINOMA; URINE LEVEL;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOKINES, CXC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0032145962     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00188-5     Document Type: Article

References (47)

1. Morales A., Eidinger D., Bruce A.W. Intracavitary bacille Calmette-Guérin (BCG) in the treatment of superficial bladder tumors. J Urol. 116:1976;180-183.
2. Herr H.W., Laudone V.P., Whitmore W.F. Jr. An overview of intravesical therapy for superficial bladder tumors. J Urol. 138:1987;1363-1368.
3. Grossman H.B. Superficial bladder cancer decreasing the risk of recurrence . Oncology. 10:1996;1617-1624.
4. Kavoussi L.R., Brown E.J., Ritchey J.K., et al. Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa requirement for the expression of an antitumor response . J Clin Invest. 85:1990;62-67.
5. Cheng D.L., Shu W.P., Choi J.C., et al. Bacillus Calmette-Guerin interacts with the carboxyl-terminal heparin binding domain of fibronectin implications for BCG-mediated antitumor activity . J Urol. 152:1994;1275-1280.
6. Becich M.J., Carroll S., Ratliff T.L. Internalization of bacille Calmette-Guerin bladder tumor cells. J Urol. 145:1991;1316-1324.
7. Prescott S., James K., Hargreave T.B., et al. Intravesical Evans strain BCG therapy quantitative immunohistochemical analysis of the immune response within the bladder wall . J Urol. 147:1992;1636-1642.
8. Böhle A., Nowc C., Ulmer A.J., et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol. 144:1990;59-64.
9. De Boer E.C., De Jong W.H., Steerenberg P.A., et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother. 34:1992;306-312.
10. Patard J.J., Muscatelli-Groux B., Saint F., et al. Evaluation of local immune response after intravesical bacille Calmette-Guerin treatment for superficial bladder cancer. Br J Urol. 78:1996;709-714.
11. Thalmann G.N., Dewald B., Baggiolini M., et al. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy a potential prognostic factor of tumor recurrence and progression . J Urol. 158:1997;1340-1344.
12. Rabinowitz R., Smith D.S., Tiemann D.D., et al. Urinary interleukin-8/creatinine level as predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. J Urol. 158:1997;1728-1732.
13. Jackson A.M., Alexandroff A.B., Kelly R.W., et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol. 99:1995;369-375.
14. Tobin MS, Wagner JR, O'Donnell MA, et al: In vitro analysis of cytokine production by normal urothelial cells in response to BCG (abstract). Meeting of the Society of Surgical Oncology, March 1995.
15. Sander B., Damm O., Gustafsson B., et al. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin. J Urol. 156:1996;536-541.
16. Sen G.C., Lengyel P. The interferon system A bird's eye view of its biochemistry . J Biol Chem. 267:1992;5017-5020.
17. Sato N., Nariuchi H., Tsuruoka N., et al. Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol. 95:(6 Suppl):1990;85S-89S.
18. Friesel R., Komoriya A., Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol. 104:1987;689-696.
19. Saiki I., Sato K., Yoo Y.C., et al. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer. 51:1992;641-645.
20. Prescott S., James K., Hargreave T.B., et al. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 144:1990;1248-1251.
21. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston Clinical applications of research on angiogenesis . N Engl J Med. 333:1995;1757-1763.
22. Gately M.K., Warrier R.R., Honasoge S., et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol. 6:1994;157-167.
23. Voest E.E., Kenyon B.M., O'Reilly M.S., et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 87:1995;581-586.
24. Sgadari C., Angiolillo A.L., Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 87:1996;3877-3882.
25. Luster A.D., Unkeless J.C., Ravetch J.V. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 315:1985;672-676.
26. Narumi S., Wyner L.M., Stoler M.H., et al. Tissue-specific expression of murine IP-10 mRNA following systemic treatment with interferon gamma. J Leukoc Biol. 52:1992;27-33.
27. Luster AD: Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med (in press).
28. Luster A.D., Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 178:1993;1057-1065.
29. Angiolillo A.L., Sgadari C., Taub D.D., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 182:1995;155-162.
30. Arenberg D.A., Kunkel S.L., Polverini P.J., et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 184:1996;981-992.
31. Ratliff T.L., Gillen D., Catalona W.J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 137:1987;155-158.
32. Ratliff T.L., Ritchey J.K., Yuan J.J., et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 150:1993;1018-1023.
33. Luster A.D., Greenberg S., Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med. 182:1995;219-231.
34. Kräling B.M., Bischoff J. A simplified method for growth of human microvascular endothelial cells results in decreased senescence and continued responsiveness to cytokines and growth factors. In Vitro Cell Dev Biol - Animal. 33:1998;308-315.
35. O'Donnell M.A., Aldovini A., Duda R.B., et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun. 62:1994;2508-2514.
36. de Reijke T.M., deBoer E.C., Kurth K.H., et al. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer processing, stability, and prognostic value . J Urol. 155:1996;477-482.
37. Okamura H., Tsutsui H., Komatsu T., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 378:1995;88-91.
38. Hayashi A., Noda A. Does the cell wall skeleton from bacille Calmette-Guerin directly induce interferon-gamma, independent of interleukin-12? Jpn J Clin Oncol. 26:1996;124-127.
39. Yu C.-L., Haskard D.O., Cavender D., et al. Human gamma interferon increases the binding of T lymphocytes to endothelial cells. Clin Exp Immunol. 62:1985;554-560.
40. Shapiro S.D., Campbell E.J., Kobayashi D.K., et al. Immune modulation of metalloproteinase production in human macrophages Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma . J Clin Invest. 86:1990;1204-1210.
41. Strieter R.M., Kunkel S.L., Arenberg D.A., et al. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun. 210:1995;51-57.
42. Taub D.D., Lloyd A.R., Conlon K., et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 177:1993;1809-1814.
43. Gattass C.R., King L.B., Luster A.D., et al. Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J Exp Med. 179:1994;1373-1378.
44. Loetscher M., Gerber B., Loetscher P., et al. Chemokine receptor specific for IP10 and mig structure, function, and expression in activated T-lymphocytes . J Exp Med. 184:1996;963-969.
45. Goebeler M., Yoshimura T., Toksoy A., et al. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol. 108:1997;445-451.
46. Singh R.K., Gutrman M., Bucana C.D., et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 92:1995;4562-4566.
47. Nastala C.L., Edington H.D., McKinney T.G., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 153:1994;1697-1706.